You’re using a public version of DrugChatter with 10 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.


How does increased tigecycline dosage affect patients?

See the DrugPatentWatch profile for tigecycline

Increased tigecycline dosage may have several effects on patients, primarily related to its antibacterial properties and potential side effects. Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections, including complicated skin and intra-abdominal infections, and community-acquired pneumonia [1].

Higher dosages of tigecycline might provide increased antibacterial coverage and potentially lead to better treatment outcomes in severe infections or when treating bacteria resistant to other antibiotics [2]. However, increased dosages also increase the risk and severity of side effects [3].

Common side effects of tigecycline include nausea, vomiting, and diarrhea [1]. At higher dosages, these side effects might be more frequent or severe. Other potential adverse effects include elevated liver enzymes, changes in electrolyte levels, and rare but serious risks such as anaphylaxis and severe diarrhea caused by Clostridioides difficile [1][3].

It is essential to consider that tigecycline has a black box warning from the U.S. Food and Drug Administration (FDA) due to increased mortality rates in patients treated with tigecycline compared to other antibiotics [1]. This warning applies to all approved indications, and the reason for the increased mortality is not well understood [1]. Therefore, increasing tigecycline dosages should be carefully considered and balanced against the potential risks.

In summary, increased tigecycline dosages may offer better antibacterial coverage but also heighten the risk and severity of side effects. The use of higher dosages should be carefully evaluated, considering the individual patient's condition and the potential risks and benefits [1][2][3].

[1] U.S. Food and Drug Administration. (2017). Tygacil (tigecycline) prescribing information.
[2] Gorwitz, R. J., & Karchmer, A. W. (2016). Tigecycline: an update on its role in the treatment of skin and soft tissue infections. Expert review of anti-infective therapy, 14(5), 517–525.
[3] DrugPatentWatch. (n.d.). Tigecycline.

Other Questions About Tigecycline :  Is there a link between tigecycline overuse and decreased survival odds in severe infections? Are there any regions with high tigecycline misuse and related deaths? Are there any generic alternatives to tigecycline?

DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2024. All rights reserved. Privacy